Skip to main
IMVT
IMVT logo

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc. demonstrates a positive outlook due to the promising sustained reduction in TRAb levels during the off-treatment period, indicating the potential of FcRn blockers as disease-modifying therapies in autoimmune conditions like Graves' disease (GD). The impressive responder rate of 81% during the 6-month off-treatment phase, comparable to rates seen during active treatment, strengthens confidence in the durability of the therapeutic effect. Additionally, the effectiveness observed in patients unresponsive to conventional anti-thyroid drug therapy underlines the significant clinical value of Immunovant's innovative approach to treating autoimmune diseases.

Bears say

Immunovant Inc. faces a negative outlook due to the implications of persistently high TRAbs, which are linked to increased relapse rates in patients. The company's primary focus on developing IMVT-1402 as a treatment for autoimmune diseases may be compromised by the potential complications arising from TRAbs-mediated TSHR activation, which can lead to significant health risks such as inflammation and vision impairment. Additionally, the challenges associated with managing these adverse effects could hinder the company's developmental progress and market potential, thereby impacting its overall financial stability.

Immunovant Inc (IMVT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 7 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.